Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma

<div>GSEA results showing the highly activated pathways in FCRL-determined high-risk and low-risk groups. (a) The activated signaling pathways in FCRL-determined high-risk group. (b) The activated signaling pathways in FCRL-determined low-risk group.</div>

BioMed Research International

fig5

Figure 5

Figure 5: Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma 